

CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:

215341Orig1s000

Trade Name: Kerendia

Generic or Proper Name: finerenone

Sponsor: Bayer HealthCare Pharmaceuticals, Inc.

Approval Date: July 9, 2021

Indication: To reduce the risk of sustained eGFR decline, end stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D).

CENTER FOR DRUG EVALUATION AND RESEARCH

215341Orig1s000

CONTENTS

Reviews / Information Included in this NDA Review.

Approval Letter	X
Other Action Letters	
Labeling	X
REMS	
Officer/Employee List	X
Integrated Review(s)	X
Product Quality Review(s)	X
Other Reviews	X
Risk Assessment and Risk Mitigation Review(s)	X
Proprietary Name Review(s)	X
Administrative/Correspondence Document(s)	X

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

215341Orig1s000

APPROVAL LETTER

NDA 215341

NDA APPROVAL

Bayer HealthCare Pharmaceuticals, Inc.
Attention: Dan Kim, Pharm.D., MBA
Associate Director, Global Regulatory Affairs
100 Bayer Blvd., P.O. Box 915
Whippany, NJ 07981-0915

Dear Dr. Kim:

Please refer to your new drug application (NDA) dated November 6, 2020, received November 9, 2020, and your amendments, submitted under section 505(b)(1) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Kerendia (finerenone) tablets.

This NDA provides for the use of Kerendia (finerenone) tablets to reduce the risk of sustained eGFR decline, end stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D).

APPROVAL & LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.¹ Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information), as well as annual reportable changes not included in the enclosed labeling. Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.²

CARTON AND CONTAINER LABELING

Submit final printed carton and container labeling that are identical to the enclosed carton labeling submitted on July 6, 2021, and enclosed container labeling submitted on May 26, 2021, as soon as they are available, but no more than 30 days after they are

¹ <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>

printed. Please submit these electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications*. For administrative purposes, designate this submission “Final Printed Carton and Container Labeling for approved NDA 215341.” Approval of this submission by FDA is not required before the labeling is used.

DATING PERIOD

Based on the stability data submitted to date, the expiry dating period for Kerendia (finerenone) tablets shall be 36 months from the date of manufacture when stored at 20°C to 25°C (68°F to 77°F) in the commercial packaging. Excursions are permitted from 15°C to 30°C (59°F to 86°F).

ADVISORY COMMITTEE

Your application for Kerendia was not referred to an FDA advisory committee because the application did not raise significant safety or efficacy issues in the intended population.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We are waiving the pediatric study requirement for this application because necessary studies are impossible or highly impracticable.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the final guidance for industry *Providing Regulatory Submissions in Electronic and Non-Electronic Format—Promotional Labeling and Advertising Materials for Human Prescription Drugs*.²

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials and the Prescribing Information at the time of initial dissemination or publication,

² For the most recent version of a guidance, check the FDA guidance web page at <https://www.fda.gov/media/128163/download>.

accompanied by a Form FDA 2253. Form FDA 2253 is available at FDA.gov.³
Information and Instructions for completing the form can be found at FDA.gov.⁴

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

POST APPROVAL FEEDBACK MEETING

New molecular entities qualify for a post approval feedback meeting. Such meetings are used to discuss the quality of the application and to evaluate the communication process during drug development and marketing application review. The purpose is to learn from successful aspects of the review process and to identify areas that could benefit from improvement. If you would like to have such a meeting with us, call the Regulatory Project Manager for this application.

If you have any questions, please call Anna Park, Regulatory Project Manager, at (301) 796-1129.

Sincerely,

{See appended electronic signature page}

Ellis Unger, M.D.
Director
Office of Cardiology, Hematology,
Endocrinology, and Nephrology
Center for Drug Evaluation and Research

ENCLOSURES:

- Content of Labeling
 - Prescribing Information
- Carton and Container Labeling

³ <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>

⁴ <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

ELLIS F UNGER
07/09/2021 12:57:51 PM